All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

The Surprising Connection Between Male Infertility and Family Cancer Risk

May 6th 2024

In a recent study, researchers at Huntsman Cancer Institute found a trend in families with male infertility: an increased risk of certain cancers.

Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML

May 6th 2024

Uproleselan plus chemotherapy did not achieve a statistically significant improvement in OS vs chemotherapy alone in patients with relapsed/refractory AML.

EMA Validates MAA for Frontline Nivolumab/Ipilimumab for MSI-H/dMMR mCRC

May 6th 2024

The European Medicines Agency has validated an application for nivolumab plus ipilimumab for frontline MSI-H/dMMR metastatic colorectal cancer.

FDA Accepts BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

May 6th 2024

The FDA has accepted a biologics license application for subcutaneous nivolumab for adult patients eligible for approved solid tumor nivolumab indications.

AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward

May 6th 2024

Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.

Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL

May 6th 2024

Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

May 6th 2024

Darolutamide uptake in metastatic hormone-sensitive prostate cancer has become routine both in doublet and triplet regimens in community urology practices.

TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer

May 5th 2024

TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.

Dr Kutikov on Therapeutic Approaches in Urothelial Cancer Requiring Cystectomy

May 5th 2024

Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.

Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC

May 5th 2024

Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).

Nadofaragene Firadenovec Demonstrates Durable 5-Year Activity in NMIBC

May 5th 2024

Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003.

UGN-102 With/Without TURBT Produces Similar DOR and DFS in Newly Diagnosed and Recurrent NMIBC

May 5th 2024

UGN-102 with/without TURBT displayed meaningful and similar DFS and DOR rates in newly diagnosed and recurrent low-grade intermediate-risk NMIBC.

Dr Wang on the Role of Active Surveillance in Patients With Renal Masses

May 4th 2024

Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.

Dr Meeks on Harnessing Innovation in Bladder Cancer

May 4th 2024

Joshua J. Meeks, MD, PhD, discusses effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.

PSMA-PET Plus Multi-Parametric MRI Aids Detection of Clinically Significant Prostate Cancer

May 4th 2024

18F-DCFPyL PSMA-PET imaging plus multi-parametric MRI improved the detection of clinically significant prostate cancer in low- and high-risk men on active surveillance.

Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC

May 4th 2024

Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.

Dr Shore on the Importance of a Multidisciplinary Team in Urologic Oncology

May 3rd 2024

Neal Shore, MD, FACS, discusses the importance of a multidisciplinary team in light of recent developments in urologic oncology.

Apalutamide/ADT Demonstrates 100% Biochemical RFS Rate in High-Risk Prostate Cancer

May 3rd 2024

Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.

Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

May 3rd 2024

Outcome improvements with lutetium Lu 177 vipivotide tetraxetan vs ARPI change favored prior treatment with abiraterone vs enzalutamide in mCRPC.

18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer

May 3rd 2024

18F-PSMA-1007 PET/CT generated superior locoregional staging results vs multiparametric MRI in patients with prostate cancer.